BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19362505)

  • 1. Thiazolidinediones: antidiabetic agents with effects on bone.
    Debiais F
    Joint Bone Spine; 2009 May; 76(3):221-3. PubMed ID: 19362505
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.
    Schwartz AV; Sellmeyer DE
    Expert Opin Drug Saf; 2008 Jan; 7(1):69-78. PubMed ID: 18171315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone increases bone resorption in women with type 2 diabetes: a randomized, controlled trial.
    Gruntmanis U; Fordan S; Ghayee HK; Abdullah SM; See R; Ayers CR; McGuire DK
    Calcif Tissue Int; 2010 May; 86(5):343-9. PubMed ID: 20354684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
    Yaturu S; Bryant B; Jain SK
    Diabetes Care; 2007 Jun; 30(6):1574-6. PubMed ID: 17363747
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
    Lecka-Czernik B
    Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.
    Berberoglu Z; Yazici AC; Demirag NG
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):305-12. PubMed ID: 20148906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
    Loke YK; Singh S; Furberg CD
    CMAJ; 2009 Jan; 180(1):32-9. PubMed ID: 19073651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of thiazolidinediones on bone loss and fracture.
    Murphy CE; Rodgers PT
    Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2 diabetes, thiazolidinediones: bad to the bone?
    Watts NB; D'Alessio DA
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3276-8. PubMed ID: 16960122
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetes drug pioglitazone (Actos): risk of fracture.
    Meymeh RH; Wooltorton E
    CMAJ; 2007 Sep; 177(7):723-4. PubMed ID: 17823139
    [No Abstract]   [Full Text] [Related]  

  • 12. Thiazolidinediones: do harms outweigh benefits?
    Lipscombe LL
    CMAJ; 2009 Jan; 180(1):16-7. PubMed ID: 19073650
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats.
    Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
    Douglas IJ; Evans SJ; Pocock S; Smeeth L
    PLoS Med; 2009 Sep; 6(9):e1000154. PubMed ID: 19787025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus.
    Mori H; Okada Y; Tanaka Y
    Intern Med; 2017; 56(11):1301-1306. PubMed ID: 28566590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of thiazolidinediones on BMD and osteoporosis.
    McDonough AK; Rosenthal RS; Cao X; Saag KG
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):507-13. PubMed ID: 18695700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
    Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
    J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione use and the risk of fractures.
    Toulis KA; Goulis DG; Anastasilakis AD
    CMAJ; 2009 Apr; 180(8):841-2; author reply 842-3. PubMed ID: 19364796
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
    Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
    Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.